Cargando…

Dialysis Procedures Alter Metabolic Conditions

A progressive chronic kidney disease results in retention of various substances that more or less contribute to dysfunction of various metabolic systems. The accumulated substances are denominated uremic toxins. Although many toxins remain undetected, numerous newly defined toxins participate in the...

Descripción completa

Detalles Bibliográficos
Autor principal: Stegmayr, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490527/
https://www.ncbi.nlm.nih.gov/pubmed/28554992
http://dx.doi.org/10.3390/nu9060548
_version_ 1783247000007868416
author Stegmayr, Bernd
author_facet Stegmayr, Bernd
author_sort Stegmayr, Bernd
collection PubMed
description A progressive chronic kidney disease results in retention of various substances that more or less contribute to dysfunction of various metabolic systems. The accumulated substances are denominated uremic toxins. Although many toxins remain undetected, numerous newly defined toxins participate in the disturbance of food breakdown. In addition, toxic effects may downregulate other pathways, resulting in a reduced ability of free fatty acid breakdown by lipoprotein lipase (LPL) and hepatic lipase (HL). Dialysis may even worsen metabolic functions. For LPL and HL, the use of heparin and low molecular weight heparin as anticoagulation during hemodialysis (HD) initiate a loss of these enzymes from their binding sites and degradation, causing a temporary dysregulation in triglyceride breakdown. This lack of function will cause retention of the triglyceride containing lipids for at least 8 h. In parallel, the breakdown into free fatty acids is limited, as is the energy supply by them. This is repeated thrice a week for a normal HD patient. In addition, dialysis will cause a loss of amino acids and disturb glucose metabolism depending on the dialysates used. The addition of glucose in the dialysate may support oxidation of carbohydrate and the retention of Amadori products and subsequent tissue alterations. To avoid these effects, it seems necessary to further study the effects of anticoagulation in HD, the extent of use of glucose in the dialysate, and the supplementation of amino acids.
format Online
Article
Text
id pubmed-5490527
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-54905272017-07-03 Dialysis Procedures Alter Metabolic Conditions Stegmayr, Bernd Nutrients Review A progressive chronic kidney disease results in retention of various substances that more or less contribute to dysfunction of various metabolic systems. The accumulated substances are denominated uremic toxins. Although many toxins remain undetected, numerous newly defined toxins participate in the disturbance of food breakdown. In addition, toxic effects may downregulate other pathways, resulting in a reduced ability of free fatty acid breakdown by lipoprotein lipase (LPL) and hepatic lipase (HL). Dialysis may even worsen metabolic functions. For LPL and HL, the use of heparin and low molecular weight heparin as anticoagulation during hemodialysis (HD) initiate a loss of these enzymes from their binding sites and degradation, causing a temporary dysregulation in triglyceride breakdown. This lack of function will cause retention of the triglyceride containing lipids for at least 8 h. In parallel, the breakdown into free fatty acids is limited, as is the energy supply by them. This is repeated thrice a week for a normal HD patient. In addition, dialysis will cause a loss of amino acids and disturb glucose metabolism depending on the dialysates used. The addition of glucose in the dialysate may support oxidation of carbohydrate and the retention of Amadori products and subsequent tissue alterations. To avoid these effects, it seems necessary to further study the effects of anticoagulation in HD, the extent of use of glucose in the dialysate, and the supplementation of amino acids. MDPI 2017-05-27 /pmc/articles/PMC5490527/ /pubmed/28554992 http://dx.doi.org/10.3390/nu9060548 Text en © 2017 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Stegmayr, Bernd
Dialysis Procedures Alter Metabolic Conditions
title Dialysis Procedures Alter Metabolic Conditions
title_full Dialysis Procedures Alter Metabolic Conditions
title_fullStr Dialysis Procedures Alter Metabolic Conditions
title_full_unstemmed Dialysis Procedures Alter Metabolic Conditions
title_short Dialysis Procedures Alter Metabolic Conditions
title_sort dialysis procedures alter metabolic conditions
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490527/
https://www.ncbi.nlm.nih.gov/pubmed/28554992
http://dx.doi.org/10.3390/nu9060548
work_keys_str_mv AT stegmayrbernd dialysisproceduresaltermetabolicconditions